StockNews.AI
OCUL
StockNews.AI
176 days

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

1. Conference call on March 3 will cover Q4 and full-year results. It is a scheduled investor update. 2. AXPAXLI in Phase 3 for wet AMD is highlighted. It may draw investor confidence. 3. Pipeline products DEXTENZA and PAXTRAVA are noted for continued innovation. It underscores Ocular’s development strategies.

Earnings
-2.93%Current Return
VS
-0.7%S&P 500
$702/24 07:08 AM EDTEvent Start
$6.79502/25 01:44 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The announcement is a routine earnings call invite and does not reveal new data. Similar past calls typically resulted in limited immediate price movement.

How important is it?

While the announcement is standard, forthcoming financial details may influence short-term trading. The event’s outcome could temporarily impact OCUL’s price.

Why Short Term?

Earnings announcements can cause near-term volatility once detailed financials are disclosed. Historical patterns show short-term price adjustments around such events.

Related Companies

February 24, 2025 07:00 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201) 689-8470 Conference ID: 13750940 Webcast Access: Please click here The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Follow the Company on its website, LinkedIn, or X. The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com

Related News